Jon Win's questions to AbbVie Inc (ABBV) leadership • Q4 2024
Question
An analyst from UBS asked if there were any notable Q4 trends in stocking or gross-to-net patterns ahead of the Part D changes and requested more geographic color on the expected aesthetics recovery, particularly the U.S. versus China.
Answer
EVP & CFO Scott Reents stated there was minimal stocking impact in Q4 and no unusual gross-to-net dynamics for Skyrizi and Rinvoq. SVP Carrie Strom explained that while the U.S. and China remain key markets, Japan is also a growth driver. She noted that new product launches in China are helping drive share and expects the international business to increase as a percentage of total aesthetics revenue over time.